Related references
Note: Only part of the references are listed.Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria
Ya-Wen Hung et al.
LIVER CANCER (2021)
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
Masahiro Morita et al.
LIVER CANCER (2021)
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2020)
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
Pei-Chang Lee et al.
CANCERS (2020)
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
Mallika Lala et al.
EUROPEAN JOURNAL OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Atsushi Hiraoka et al.
LIVER CANCER (2019)
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma
I-Cheng Lee et al.
LIVER INTERNATIONAL (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma
Pei-Chang Lee et al.
LIVER INTERNATIONAL (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R. Hui et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
